Five Alarm Bio is targeting an unexplored mechanism of aging to delay or prevent the onset of a broad range of age-related diseases.  Our novel approach leverages well-known, inherently safe biology with broad potential therapeutic application. Our small molecules promise to be potential treatments for a range of diseases and disabilities, enabling healthier and more fulfilling lives for older people.

Founded in 2016 by three experienced entrepreneurs, Five Alarm Bio is based near Cambridge, UK, and is carrying out research at the Babraham Campus.

img

Who we are

  • Janette Thomas

    CEO

    Janette has a background in Biochemistry research at Leicester and Cambridge, after which she has had 25years of pharmaceutical drug discovery and development experience from large Pharma (GSK) and SME’s. She has been instrumental in the early strategy and growth of small companies including Horizon Discovery (now a public company). She was Director of International Operations at Atlantic Healthcare until she founded Pellis Care Ltd. As a member of leadership teams, Janette has broad experience in developing company and product R&D strategy. Examples of her expertise include the successful completion of commercial-scale oligonucleotide manufacturing process, submission of regulatory dossiers, and invention and grant of patents. She has managed multinational projects for charities and not-for-profits to find new treatments for Malaria and led InnovateUK grants through to successful completion.

  • William Bains

    CSO

    William is a scientist and entrepreneur with a 30-year track record research into the fundamentals of biology and translating that research into new enterprises.William has a BA in biochemistry from Oxford University,a PhD in molecular biology from Warwick, and did a postdoc at Stanford and a lectureship at Bath before joining PA Consulting Group’s Technology division. In 1998 Dr. Bains joined a boutique London VC group as head of science,and he was founder and CSO of his first start-up in 2001. Dr. Bains research focuses on the chemical nature of life, it’s limits and it’s failures, especially in ageing. He is author of over 100 papers on subjects as diverse as drug chemistry, anti-aging drugs, sewage plant management, company law and extra-terrestrial life, as well as five books. William continues active scientific research in collaboration with MIT and Cardiff University. He has taught at Bath, Warwick and Cambridge Universities, and is a frequent speaker to University, conference and non-scientific audiences.

  • Peter Tyrer

    Lead Research Scientist

    Peter is a biologist with almost 30 years industrial and academic experience in therapeutics discovery methods and their deployment, including the preclinical development of an oncology drug which went on to successful launch. He has worked across the biomedical industry in large pharmaceutical companies such as  in Merck, Sharp & Dohme and AstraZeneca, established biotech companies such as Celltech, and small start-ups such as Provalis. He has specialising in using cell biological techniques in drug discovery, especially in immunology. His last job before joining Five Alarm Bio was at Enplas, leading the biological development of a cutting-edge organ-on-a-chip technology. Peter holds a BSc from University of Liverpool (UK) and a PhD from University of Canberra (Australia).

  • Hannah Mizen

    Research Scientist

     Hannah is a cell biologist with expertise in ageing and longevity research, specifically the role of cellular senescence. She has recently completed an interdisciplinary PhD and Post-Doc at Queen Mary University of London, and has prior experience whilst collaborating with Unilever, with further industry experience working for AstraZeneca. Hannah holds a Bsc from the University of Leicester. 

  • Ann Baker

    Director

    Ann has more than 25 years of experience working on strategy and business consulting engagements with companies in the pharmaceuticals, biotech, and medical devices sectors. She specializes in working with the R&D functions of life sciences companies. Until recently she worked for Charles River Associates as VP of their life sciences Practice. Before joining CRA, Ms. Baker co-founded Atkinson Cowan, a life sciences consulting firm in London. Previously, she was a partner with Accenture in the Health and Life Sciences Group and led the Pharmaceutical R&D Practice in the UK. She also worked for PA Consulting Group, and led the Pharmaceutical Strategy Group in its Melbourn, UK facility and the Technology Strategy Group in the US. Ms. Baker holds an MA (Hons) in Zoology from the University of Oxford and a BA (Hons) in History from The Open University.

  • Janette Thomas

    CEO

    Janette has a background in Biochemistry research at Leicester and Cambridge, after which she has had 25years of pharmaceutical drug discovery and development experience from large Pharma (GSK) and SME’s. She has been instrumental in the early strategy and growth of small companies including Horizon Discovery (now a public company). She was Director of International Operations at Atlantic Healthcare until she founded Pellis Care Ltd. As a member of leadership teams, Janette has broad experience in developing company and product R&D strategy. Examples of her expertise include the successful completion of commercial-scale oligonucleotide manufacturing process, submission of regulatory dossiers, and invention and grant of patents. She has managed multinational projects for charities and not-for-profits to find new treatments for Malaria and led InnovateUK grants through to successful completion.

  • William Bains

    CSO

    William is a scientist and entrepreneur with a 30-year track record research into the fundamentals of biology and translating that research into new enterprises.William has a BA in biochemistry from Oxford University,a PhD in molecular biology from Warwick, and did a postdoc at Stanford and a lectureship at Bath before joining PA Consulting Group’s Technology division. In 1998 Dr. Bains joined a boutique London VC group as head of science,and he was founder and CSO of his first start-up in 2001. Dr. Bains research focuses on the chemical nature of life, it’s limits and it’s failures, especially in ageing. He is author of over 100 papers on subjects as diverse as drug chemistry, anti-aging drugs, sewage plant management, company law and extra-terrestrial life, as well as five books. William continues active scientific research in collaboration with MIT and Cardiff University. He has taught at Bath, Warwick and Cambridge Universities, and is a frequent speaker to University, conference and non-scientific audiences.

  • Sunil Shah

    Director

    Sunil has been active in the early stage biotech community in the UK since the mid 1990’s, his MBA thesis at Cambridge addressed issues virtualised networks in science. He started his career in the life sciences team at PA consulting group, followed by co-founding a tech company that gained public prominence between 1999 to 2003.In 2003 Sunil co-founded Oxygen Healthcare, which he grew into an integrated drug discovery services business specialising in chemistry and biology, with clients from the USA, Japan and the EU. The company grew into a team of 350 employees including a 100,000 sq. ft. purpose built greenfield development. Piramal Enterprises (NSE:PEL) acquired the business in 2011-2013. o2h Ventures was co-founded by Sunil in 2013. In the last 3-4 years, he has co-founded four companies with UK based academics and entrepreneurs, held Chairman or Director level positions in nine companies, built up a portfolio of twenty early stage investments, and executed early stage drug discovery research projects for fifteen different companies.

  • João Pedro de Magalhães

    Advisor

    João Pedro de Magalhães is Professor of Molecular Biogerontology at the University of Birmingham, UK. He graduated in Microbiology in 1999 from the Escola Superior de Biotecnologia in his hometown of Porto, Portugal, and in 2004 obtained a PhD in Biological Sciences from the University of Namur in Belgium. Following further training in computational biology and genetics at Harvard Medical School (Boston, USA), in 2008 Dr de Magalhaes joined the University of Liverpool in the UK as a faculty member to develop his own group on genomic approaches to ageing. His research on genetics, ageing and longevity has widely been featured in scientific magazines (Science, Nature, Scientific American, New Scientist, etc.). In addition, he has a long-term interest in technological trends and their future impact on society. His work on predicting how technology will shape the human condition has been published in magazines such as Futures and The Futurist, and in newspapers like The Independent. Dr de Magalhaes has given over 100 invited talks, including a TEDx talk, and makes regular media appearances (BBC, CNN, the Washington Post, the Financial Times and many others). He is also an advisor/consultant or various organizations, including nonprofit foundations and biotech companies. For more information please see the personal website of Dr de Magalhaes http://jp.senescence.info/

  • David Weinkove

    Advisor

    David Weinkove is a Professor at the Department of Biosciences, Durham University and Chair of the British Society for Research on Ageing (since 2022). In 2018, David cofounded Magnitude Biosciences, as a spinout of Durham University, to provide C. elegans services to companies developing drugs and other products to slow ageing and treat age-related disease and he is currently CSO of this company. In his academic research, David has worked with the nematode C. elegans for 25 years, using it as a model to understand basic biology, in particular how bacteria can influence aging, and the role of micronutrients.

  • Andy Morley

    Advisor

    Andy is a creative and innovative medicinal chemist with extensive knowledge and expertise, and is author and inventor on >50 patents and publications. He has twenty one years experience working in the pharmaceutical industry, with a track record of delivery across all phases of the drug discovery process having contributed to progression of candidates to the clinic across several therapy areas (Cardiovascular, Respiratory, Inflammatory).

  • Barry Bentley

    Advisor

    Barry L. Bentley is a Reader in Bioengineering, Head of the Bioengineering Research Group, and Deputy Director of the EUREKA Robotics Centre at Cardiff Metropolitan University. He is also a Fulbright Scholar in the Center for Engineering in Medicine and Surgery at Harvard Medical School and Massachusetts General Hospital, a Fellow of the Royal Society of Biology, Fellow of the Foresight Institute, Fellow of the Higher Education Academy, and a CASMI Fellow at UCL.


    Barry received his Ph.D. degree from the University of Cambridge, where he worked at the MRC Laboratory of Molecular Biology to map and analyse the neuromodulatory connectome of C. elegans. Barry has conducted research and consultancy work for numerous organisations including the University of Oxford, the European Space Agency, London Business School, and ARM Holdings. His current research focuses on laboratory systems for biopreservation, and the development of classification and staging systems for age-related pathology within the context of the WHO ICD-11.

Aging is the number one cause of disability and morbidity in our society, and the cause of the biggest drain of resources on the healthcare systems in the Western world.

We are pursuing a fundamentally new approach to anti-aging to invent new pharmaceuticals that will prevent and treat chronic disease. We are investigating a biological pathway and mechanisms, and synthesising and screening new chemical compounds, to find  interventions that enable a longer life of functionally healthy cells and organisms. By targeting an unexplored mechanism of aging we aim to delay or prevent the onset of a broad range of age-related diseases.

See the other sections for more background on the chemistry and biology of aging, and how Five Alarm Bio is targeting it.

img

Our bodies are assaulted by chemicals every second. If we drank nothing but pure water and ate only the cleanest, healthiest food, the oxygen in the air we breathe is a reactive substance that damages us and causes our own metabolisms to generate ‘accidental’ products that are harmful.

In a landmark paper published in 2016, Five Alarm Bio’s founding scientist William Bains described why any chemical that was not part of the body’s healthy biochemistry is bound to interfere with the actions of enzymes and other proteins throughout the body. Even small changes in how a protein functions can disrupt the delicate balance of a healthy cell.

Luckily our cells have many defences against such disruption, but they gradually fade with age. A key development of the 2016 work was seeing how a small molecule could be used to make those defences work harder, to counter the effect of aging on our chemical defences and hence extend healthy lifespan. This is the technology that Five Alarm Bio is implementing.

img

Five Alarm Bio's foundational science has shown that targeting the chemical damage of aging can modulate a range of fundamental aging processes. We have used a model 'probe' compound to test what effects modulating Five Alarm's target mechanism will have. Working with primary human skin cells, we have shown that we can reduce cell senescence, reduce the chemical damage that accumulated in aged cells, and reduce the decline in their ability to heal a 'wound' in cell culture. We have also worked with Magnitude Biosciences to test the effect of our probe on aging in the nematode worm C. elegans. C. elegans is a well-tested model for aging in animals, and has been the organism that pioneered many breakthroughs in aging research. Magnitude have shown that our probe extends the healthspan of C. elegans by ~40%, a result that Magnitude Head of Experiments Michael Fasseas said was "One of the best results we have seen".

img

Five Alarm Bio in using high-content imaging to screen new molecules for their ability to boost the cell's defence against age-related damage. Based on our 'probe' molecule, as well as a number of others that we have identified, we have found candidates that are over 100 times more potent than the original, and which have potential to return cellular function to a much 'younger' state.

We have tested the first of these in a simple model of wound healing, achieving double of the rate at which a wound in a layer of cells heals itself in the presence of our compound.

The mechanism also has the potential to treat neurodegenerative diseases. We have started collaborations with Principal Scientists at the Babraham Institute and the University of Bath on this exciting research area, with more details in the News section of this site.





Five Alarm therapeutics pipeline
img
News

Five Alarm Bio and Proteotype start a major grant-funded collaboration February 2025
Five Alarm Bio ha started a collaborative research project with Proteotype Diagnostics Ltd. to apply Proteotype's PCS proteome characterization technology to tracking how Five Alarm's compounds can reduce cell senescence. The project is funded by a grant from The Babraham Research Campus. See here for more information.


Five Alarm Bio presents latest research at Royal Society of Chemistry conference January 2025
Five Alarm Bio's research has been selected for presentation as a poster at the Royal Society of Chemistry's meeting on Drugging the Multimorbidity Associated with Ageing, held in London in January 2025. See here for the conference's web site, and this link for our Poster presenting the latest results from our research.


Five Alarm Bio is awarded Green Impact Gold Award. July 2024
Five Alarm Bio is proud to have been awarded Gold by the Babraham Research Campus Green Impact scheme for our contribution to sustainable research See here for more details


Five Alarm Bio starts collaboration on cognitive decline June 2024
Five Alarm Bio has started a pilot study in using Zebrafish as a model for cognitive decline with the Drs. Gurevich and Nikolaou at the University of Bath. See here for more details


Five Alarm Bio presents results at scientific conference May 2024
Five Alarm Bio presented the functional anti-aging results from our research at the first UK Proteostasis Conference at Babraham on 8th and 9th May, See here for our poster presenting these exciting results.


Five Alarm Bio starts research collaboration with Babraham scientist April 2024
Five Alarm Bio has started our research programme at the world-class Babraham Research Campus, near Cambridge. See here for more details.


Five Alarm Bio Raises over £500k Seed Investment February 2023
Five Alarm Bio announces closing a Seed Round investment of over £500,000 from Cambridge Angels, Meltwind, o2h Ventures, SyndicateRoom, and Angel investors, with support from KPMG Acceleris. See here for more details.


Five Alarm Bio commits to minimize ecological footprint whilst prioritising novel research. November 2023
Five Alarm Bio are now members of the 2023-2024 Babraham Research Campus Green Impact Scheme, a UNESCO award-winning programme, which supports and tracks their commitment to environmentally sustainable practices. See here for more information.

Five Alarm Bio starts research at the Babraham Research Campus October 2022
Five Alarm Bio has started our research programme at the world-class Babraham Research Campus, near Cambridge. See here for more details.


Five Alarm Bio wins O2h 'Kickstarter' competition September 2022
Five Alarm Bio has won one of O2h Discovery's Kickstarter awards to provide cost-effective chemistry services to complement our biology discovery pipeline. See here for more details.


Five Alarm Bio appoints CEO July 2022
Five Alarm Bio is pleased to announce the appointment of Dr Janette Thomas as the new Chief Executive Officer (CEO) of the company, to take us forward to the next phase of growth. See here for more details.


Five Alarm Bio's test molecule shows anti-aging effect March 2022
Five Alarm Bio has collaborated with Magnitude Biosciences to test its technology in the worm C. elegans, showing a 40% incresae in healthspan in this well-tested model organism. See here for more details.


Five Alarm Bio wins BioMedical Catalyst grant February, 2022
Five Alarm Bio has won a grant worth £360,000 from InnovateUK's prestigious Biomedical Catalyst programme to take our programme in the treatment of chronic wounds forward. See here for more details.

img

Publications

Publications from Five Alarm

img
Vacancies

Five Alarm Bio is not hiring right now

Watch our website for future opportunities.